US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD

34.87

+0.96502.85%

Volume:660.15K

Turnover:22.95M

Market Cap:2.12B

PE:-11.18

High:35.16

Open:34.00

Low:34.00

Close:33.90

52wk High:38.67

52wk Low:13.22

Shares:60.68M

Float Shares:47.61M

Volume Ratio:0.82

T/O Rate:1.39%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.1192

EPS(LYR):-2.3276

ROE:-25.28%

ROA:-17.53%

PB:2.75

PE(LYR):-14.98

Loading ...

Overview Company News Filings

Stock Track | Structure Therapeutics (GPCR) Soars 5% Pre-Market on Promising Obesity Drug Results

Press Release: Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

The Bull Case For Structure Therapeutics (GPCR) Could Change Following Key Oral Obesity Drug Data Readouts

Simply Wall St.

Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics Inc expected to post a loss of 39 cents a share - Earnings Preview

Structure Therapeutics Inc. unveils strategy to expand access to oral obesity treatments

Structure Therapeutics Q3 loss widens to $65.7 mln

BRIEF-Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million

Septerna to Participate in Upcoming Investor Conferences

Citi adds ‘positive 90-day catalyst watch’ on Structure Therapeutics

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

SIHUAN PHARM (00460) Signs Collaboration Agreement with U.S.'s AbaloneBio to Jointly Develop Next-Generation Weight Loss and Muscle-Building Therapy, Further Expanding GPCR Target Portfolio

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Piper Sandler

Structure Therapeutics (GPCR): Assessing Valuation After Recent Share Price Surge

Simply Wall St.

Press Release: Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from LifeSci Capital

Structure Therapeutics Inc. to Participate in Cantor Global Healthcare Conference

Septerna to Participate in Upcoming Investor Conferences

Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/GPCR/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GPCR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","market":"US","secType":"STK","nameCN":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","latestPrice":34.865,"timestamp":1762894800000,"preClose":33.9,"halted":0,"volume":660150,"delay":0,"floatShares":47612800,"shares":60677640,"eps":-3.119226,"marketStatus":"Pre-Mkt","change":0.965,"latestTime":"11-12 07:47:11 EST","open":34,"high":35.155,"low":34,"amount":22953257.064,"amplitude":0.034071,"askPrice":35.25,"askSize":110,"bidPrice":31.88,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.119226,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1762957800000},"marketStatusCode":1,"adr":0,"adrRate":3,"listingDate":1675400400000,"exchange":"NASDAQ","adjPreClose":34.865,"postHourTrading":{"tag":"盘后","latestPrice":35.1988,"preClose":34.865,"latestTime":"19:29 EST","volume":9755,"amount":341180.118,"timestamp":1762907373074},"volumeRatio":0.822834809765601,"impliedVol":1.907,"impliedVolPercentile":1},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GPCR\",,,,,undefined,":{"symbol":"GPCR","floatShares":47612800,"roa":"-17.53%","roe":"-25.28%","lyrEps":-2.327592,"volumeRatio":0.822834809765601,"shares":60677640,"dividePrice":0,"high":35.155,"amplitude":0.034071,"preClose":33.9,"low":34,"week52Low":13.22,"pbRate":"2.75","week52High":38.67,"institutionHeld":0,"latestPrice":34.865,"committee":-0.047619,"eps":-3.119226,"divideRate":0,"volume":660150,"delay":0,"ttmEps":-3.119226,"open":34,"prevYearClose":27.12,"prevWeekClose":32.84,"prevMonthClose":33.32,"prevQuarterClose":28,"fiveDayClose":34.01,"twentyDayClose":30.13,"sixtyDayClose":19.96},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GPCR\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"GPCR","fiscalQuarterEnding":"2025/09","expectedEps":-0.36,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"post","actualEps":-0.37},{"market":"US","date":"2025-08-06","symbol":"GPCR","fiscalQuarterEnding":"2025/06","expectedEps":-0.28,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1754452800000,"reportTimeType":"post","actualEps":-0.36},{"market":"US","date":"2025-05-08","symbol":"GPCR","fiscalQuarterEnding":"2025/03","expectedEps":-0.24,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1746676800000,"reportTimeType":"post","actualEps":-0.27},{"market":"US","date":"2025-02-27","symbol":"GPCR","fiscalQuarterEnding":"2024/12","expectedEps":-0.23,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"post","actualEps":-0.22},{"market":"US","date":"2024-11-13","symbol":"GPCR","fiscalQuarterEnding":"2024/09","expectedEps":-0.19,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1731474000000,"reportTimeType":"post","actualEps":-0.2}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GPCR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GPCR\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4,"buy":0.6,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":15,"updateTime":1757307600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GPCR\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GPCR","date":"2025-11-11","current":-11.177452,"percent":0.827637,"low":-50.180001,"twenty":-23.860402,"median":-18.309202,"eighty":-9.825436,"high":-5.211405,"avg":-18.907972,"sd":8.846191,"marketCap":1952570132},"quantilePoints":[{"date":"2023-02-03","current":-25.001825,"twenty":-43.272389,"median":-43.272389,"eighty":-32.310051,"marketCap":951294422},{"date":"2023-02-10","current":-22.116999,"twenty":-35.964163,"median":-23.496907,"eighty":-22.21316,"marketCap":841529681},{"date":"2023-02-17","current":-21.285207,"twenty":-24.521021,"median":-22.645883,"eighty":-21.915061,"marketCap":809880847},{"date":"2023-02-24","current":-23.36709,"twenty":-23.715192,"median":-22.645883,"eighty":-21.847749,"marketCap":889094402},{"date":"2023-03-03","current":-25.530709,"twenty":-24.422936,"median":-22.718004,"eighty":-21.972757,"marketCap":971417957},{"date":"2023-03-10","current":-22.636267,"twenty":-24.85566,"median":-22.790125,"eighty":-22.063149,"marketCap":861287334},{"date":"2023-03-17","current":-22.232392,"twenty":-24.422936,"median":-22.70358,"eighty":-22.09392,"marketCap":845920270},{"date":"2023-03-24","current":-21.876596,"twenty":-23.762311,"median":-22.568955,"eighty":-21.891982,"marketCap":832382619},{"date":"2023-03-31","current":-16.960589,"twenty":-23.565181,"median":-22.314128,"eighty":-21.634271,"marketCap":870434396},{"date":"2023-04-06","current":-17.823234,"twenty":-23.376706,"median":-22.232392,"eighty":-21.285207,"marketCap":914706175},{"date":"2023-04-14","current":-17.473898,"twenty":-23.36709,"median":-22.116999,"eighty":-18.643102,"marketCap":896777933},{"date":"2023-04-21","current":-17.210114,"twenty":-23.194,"median":-22.059302,"eighty":-17.623613,"marketCap":883240282},{"date":"2023-04-28","current":-17.815518,"twenty":-23.078607,"median":-21.876596,"eighty":-17.586227,"marketCap":914310203},{"date":"2023-05-05","current":-17.709107,"twenty":-22.982446,"median":-21.689083,"eighty":-17.623613,"marketCap":908849077},{"date":"2023-05-12","current":-17.00755,"twenty":-22.790125,"median":-21.491953,"eighty":-17.586227,"marketCap":956079400},{"date":"2023-05-19","current":-15.32957,"twenty":-22.780509,"median":-20.818827,"eighty":-17.473898,"marketCap":861751761},{"date":"2023-05-26","current":-19.808636,"twenty":-22.761276,"median":-19.808636,"eighty":-17.466769,"marketCap":1113542462},{"date":"2023-06-02","current":-21.830342,"twenty":-22.668962,"median":-20.674586,"eighty":-17.472472,"marketCap":1227192672},{"date":"2023-06-09","current":-23.110075,"twenty":-22.668962,"median":-21.38858,"eighty":-17.563702,"marketCap":1299132872},{"date":"2023-06-16","current":-21.061141,"twenty":-22.668962,"median":-21.491953,"eighty":-17.586212,"marketCap":1183952020},{"date":"2023-06-23","current":-21.782692,"twenty":-22.640113,"median":-21.568882,"eighty":-17.608538,"marketCap":1224514048},{"date":"2023-06-30","current":-27.561913,"twenty":-22.772816,"median":-21.571672,"eighty":-17.623492,"marketCap":1549392931},{"date":"2023-07-07","current":-24.451072,"twenty":-23.059375,"median":-21.612515,"eighty":-17.625039,"marketCap":1374517018},{"date":"2023-07-14","current":-21.428724,"twenty":-23.103781,"median":-21.707815,"eighty":-17.644282,"marketCap":1204615694},{"date":"2023-07-21","current":-23.069233,"twenty":-23.103781,"median":-21.780436,"eighty":-17.700571,"marketCap":1296836908},{"date":"2023-07-28","current":-23.552536,"twenty":-23.333385,"median":-21.782692,"eighty":-17.727736,"marketCap":1324005814},{"date":"2023-08-04","current":-21.592094,"twenty":-23.51737,"median":-21.782692,"eighty":-17.804907,"marketCap":1213799550},{"date":"2023-08-11","current":-19.978813,"twenty":-23.374783,"median":-21.781564,"eighty":-17.817061,"marketCap":1123108978},{"date":"2023-08-18","current":-16.072919,"twenty":-23.333385,"median":-21.735043,"eighty":-17.644282,"marketCap":1053531639},{"date":"2023-08-25","current":-16.66259,"twenty":-23.197654,"median":-21.646551,"eighty":-17.586168,"marketCap":1092182818},{"date":"2023-09-01","current":-16.458249,"twenty":-23.185384,"median":-21.592094,"eighty":-17.468195,"marketCap":1078788845},{"date":"2023-09-08","current":-16.680105,"twenty":-23.150918,"median":-21.568882,"eighty":-17.319402,"marketCap":1093330873},{"date":"2023-09-15","current":-18.326514,"twenty":-23.110075,"median":-21.460338,"eighty":-17.211393,"marketCap":1201248026},{"date":"2023-09-22","current":-19.937893,"twenty":-23.078607,"median":-21.067948,"eighty":-17.309925,"marketCap":1306869070},{"date":"2023-09-29","current":-21.876218,"twenty":-23.069233,"median":-21.012104,"eighty":-17.319402,"marketCap":1433920470},{"date":"2023-10-06","current":-37.165618,"twenty":-23.194,"median":-21.285207,"eighty":-17.395476,"marketCap":2436094784},{"date":"2023-10-13","current":-44.162453,"twenty":-23.552536,"median":-21.525005,"eighty":-17.459473,"marketCap":2894716299},{"date":"2023-10-20","current":-45.222784,"twenty":-23.852048,"median":-21.571672,"eighty":-17.466769,"marketCap":2964217822},{"date":"2023-10-27","current":-47.275909,"twenty":-23.892891,"median":-21.592094,"eighty":-17.469621,"marketCap":3098794020},{"date":"2023-11-03","current":-48.538851,"twenty":-24.328544,"median":-21.646551,"eighty":-17.490333,"marketCap":3181576088},{"date":"2023-11-10","current":-38.273225,"twenty":-24.864943,"median":-21.735043,"eighty":-17.514986,"marketCap":2508695101},{"date":"2023-11-17","current":-27.570058,"twenty":-25.04304,"median":-21.781564,"eighty":-17.543453,"marketCap":2122673903},{"date":"2023-11-24","current":-32.691508,"twenty":-27.365869,"median":-21.782692,"eighty":-17.586168,"marketCap":2516984612},{"date":"2023-12-01","current":-35.337541,"twenty":-28.3175,"median":-21.830342,"eighty":-17.593664,"marketCap":2720707940},{"date":"2023-12-08","current":-37.983573,"twenty":-33.138225,"median":-21.904522,"eighty":-17.623452,"marketCap":2924431267},{"date":"2023-12-15","current":-37.177707,"twenty":-34.105722,"median":-22.049686,"eighty":-17.625039,"marketCap":2862386033},{"date":"2023-12-22","current":-20.939825,"twenty":-34.105722,"median":-22.001606,"eighty":-17.644282,"marketCap":1612198995},{"date":"2023-12-29","current":-23.446258,"twenty":-34.065552,"median":-22.068918,"eighty":-17.684898,"marketCap":1805174329},{"date":"2024-01-05","current":-26.187472,"twenty":-34.000259,"median":-22.102574,"eighty":-17.702705,"marketCap":2016225834},{"date":"2024-01-12","current":-28.789086,"twenty":-33.67371,"median":-22.232392,"eighty":-17.746366,"marketCap":2216529345},{"date":"2024-01-19","current":-27.710368,"twenty":-33.290514,"median":-22.259189,"eighty":-17.804907,"marketCap":2133476670},{"date":"2024-01-26","current":-26.745867,"twenty":-33.138225,"median":-22.283013,"eighty":-17.817061,"marketCap":2059217807},{"date":"2024-02-02","current":-28.598724,"twenty":-32.691508,"median":-22.44298,"eighty":-17.823234,"marketCap":2201872991},{"date":"2024-02-09","current":-29.823387,"twenty":-32.667396,"median":-22.576119,"eighty":-17.835432,"marketCap":2296162205},{"date":"2024-02-16","current":-28.427399,"twenty":-32.293017,"median":-22.636267,"eighty":-17.890184,"marketCap":2188682272},{"date":"2024-02-23","current":-26.035182,"twenty":-31.181303,"median":-22.647193,"eighty":-17.91403,"marketCap":2004500750},{"date":"2024-03-01","current":-25.743294,"twenty":-31.092467,"median":-22.775115,"eighty":-17.959972,"marketCap":1982027673},{"date":"2024-03-08","current":-22.849791,"twenty":-30.933832,"median":-22.849791,"eighty":-18.031985,"marketCap":1759251085},{"date":"2024-03-15","current":-18.291889,"twenty":-29.823387,"median":-22.775115,"eighty":-18.031985,"marketCap":1639319082},{"date":"2024-03-22","current":-22.815466,"twenty":-29.601298,"median":-22.761276,"eighty":-18.070517,"marketCap":2044722039},{"date":"2024-03-28","current":-22.311113,"twenty":-29.398245,"median":-22.645883,"eighty":-18.070517,"marketCap":1999521939},{"date":"2024-04-05","current":-20.434088,"twenty":-29.301795,"median":-22.601624,"eighty":-18.089549,"marketCap":1831303011},{"date":"2024-04-12","current":-20.928042,"twenty":-29.107626,"median":-22.568955,"eighty":-18.098906,"marketCap":1875571150},{"date":"2024-04-19","current":-18.81184,"twenty":-29.061939,"median":-22.455039,"eighty":-18.224405,"marketCap":1685917123},{"date":"2024-04-26","current":-20.267704,"twenty":-28.863962,"median":-22.311113,"eighty":-18.256547,"marketCap":1816391638},{"date":"2024-05-03","current":-20.281918,"twenty":-28.794162,"median":-22.289169,"eighty":-18.270537,"marketCap":1817665530},{"date":"2024-05-10","current":-20.105056,"twenty":-28.789086,"median":-22.270856,"eighty":-18.288305,"marketCap":1801815151},{"date":"2024-05-17","current":-17.123915,"twenty":-28.636796,"median":-22.232392,"eighty":-18.098906,"marketCap":1672681180},{"date":"2024-05-24","current":-18.288418,"twenty":-28.476893,"median":-22.116999,"eighty":-18.062811,"marketCap":1786430959},{"date":"2024-05-31","current":-16.11295,"twenty":-28.435013,"median":-22.068918,"eighty":-17.902107,"marketCap":1573929112},{"date":"2024-06-07","current":-26.55105,"twenty":-28.381712,"median":-22.102574,"eighty":-17.902107,"marketCap":2593533072},{"date":"2024-06-14","current":-24.646705,"twenty":-28.337752,"median":-22.198735,"eighty":-17.932407,"marketCap":2407514791},{"date":"2024-06-21","current":-22.312809,"twenty":-28.3175,"median":-22.24579,"eighty":-17.974375,"marketCap":2179537500},{"date":"2024-06-28","current":-18.680713,"twenty":-28.3175,"median":-22.24579,"eighty":-18.00318,"marketCap":1824750754},{"date":"2024-07-05","current":-17.874111,"twenty":-28.267548,"median":-22.198735,"eighty":-17.932407,"marketCap":1745961056},{"date":"2024-07-12","current":-20.408464,"twenty":-28.068249,"median":-22.08815,"eighty":-17.932407,"marketCap":1993519219},{"date":"2024-07-15","current":-20.943017,"twenty":-28.006064,"median":-22.078534,"eighty":-17.941595,"marketCap":2045734877},{"date":"2024-08-02","current":-17.387286,"twenty":-27.943879,"median":-22.068918,"eighty":-17.908069,"marketCap":1698407510},{"date":"2024-08-09","current":-16.461364,"twenty":-27.802578,"median":-21.942986,"eighty":-17.823234,"marketCap":1607962532},{"date":"2024-08-16","current":-20.792004,"twenty":-27.780694,"median":-21.876596,"eighty":-17.821691,"marketCap":2088244945},{"date":"2024-08-23","current":-22.295452,"twenty":-27.74971,"median":-21.929398,"eighty":-17.823234,"marketCap":2239243758},{"date":"2024-08-30","current":-21.822777,"twenty":-27.716713,"median":-21.953525,"eighty":-17.863936,"marketCap":2191770646},{"date":"2024-09-06","current":-21.851252,"twenty":-27.691332,"median":-21.926349,"eighty":-17.874111,"marketCap":2194630472},{"date":"2024-09-13","current":-22.944669,"twenty":-27.671026,"median":-21.901472,"eighty":-17.880178,"marketCap":2304447790},{"date":"2024-09-20","current":-22.067657,"twenty":-27.608415,"median":-21.926349,"eighty":-17.902107,"marketCap":2216365150},{"date":"2024-09-27","current":-23.650834,"twenty":-27.565171,"median":-22.001606,"eighty":-17.941595,"marketCap":2375371475},{"date":"2024-10-04","current":-24.083644,"twenty":-27.536769,"median":-22.068918,"eighty":-18.000093,"marketCap":2418840830},{"date":"2024-10-11","current":-22.130301,"twenty":-27.481934,"median":-22.12365,"eighty":-18.029927,"marketCap":2222656767},{"date":"2024-10-18","current":-22.563112,"twenty":-27.163394,"median":-22.116999,"eighty":-18.055104,"marketCap":2266126122},{"date":"2024-10-25","current":-21.333018,"twenty":-26.967956,"median":-22.11226,"eighty":-18.070517,"marketCap":2142581639},{"date":"2024-10-31","current":-21.560813,"twenty":-26.932422,"median":-22.097835,"eighty":-18.080033,"marketCap":2165460247},{"date":"2024-11-08","current":-21.839862,"twenty":-26.875803,"median":-22.107521,"eighty":-18.096607,"marketCap":2193486542},{"date":"2024-11-15","current":-19.500107,"twenty":-26.820843,"median":-22.068288,"eighty":-18.16223,"marketCap":2155736838},{"date":"2024-11-22","current":-15.573182,"twenty":-26.740791,"median":-22.039183,"eighty":-18.047398,"marketCap":1721615252},{"date":"2024-11-29","current":-17.170432,"twenty":-26.702879,"median":-21.932448,"eighty":-17.923218,"marketCap":1898191276},{"date":"2024-12-06","current":-16.181125,"twenty":-26.575564,"median":-21.883856,"eighty":-17.833409,"marketCap":1788823393},{"date":"2024-12-13","current":-16.424567,"twenty":-26.524021,"median":-21.851252,"eighty":-17.817061,"marketCap":1815735909},{"date":"2024-12-20","current":-15.523314,"twenty":-26.386717,"median":-21.835102,"eighty":-17.715324,"marketCap":1716102339},{"date":"2024-12-27","current":-15.30059,"twenty":-26.269962,"median":-21.822777,"eighty":-17.687076,"marketCap":1691480250},{"date":"2025-01-03","current":-14.601342,"twenty":-26.20397,"median":-21.78933,"eighty":-17.625803,"marketCap":1614178343},{"date":"2025-01-10","current":-14.005686,"twenty":-26.17605,"median":-21.782692,"eighty":-17.604018,"marketCap":1548328570},{"date":"2025-01-17","current":-13.974608,"twenty":-26.160821,"median":-21.780436,"eighty":-17.514986,"marketCap":1544892930},{"date":"2025-01-24","current":-14.482211,"twenty":-26.10752,"median":-21.737354,"eighty":-17.469621,"marketCap":1601008389},{"date":"2025-01-31","current":-15.7046,"twenty":-26.035182,"median":-21.700984,"eighty":-17.381485,"marketCap":1736143575},{"date":"2025-02-07","current":-15.549212,"twenty":-26.032644,"median":-21.680405,"eighty":-17.295679,"marketCap":1718965373},{"date":"2025-02-14","current":-12.622728,"twenty":-25.9819,"median":-21.605123,"eighty":-17.234446,"marketCap":1395442576},{"date":"2025-02-21","current":-12.115125,"twenty":-25.903236,"median":-21.581883,"eighty":-17.21037,"marketCap":1339327118},{"date":"2025-02-28","current":-11.819887,"twenty":-25.84482,"median":-21.567582,"eighty":-17.171628,"marketCap":1306688535},{"date":"2025-03-07","current":-11.01217,"twenty":-25.735679,"median":-21.559435,"eighty":-17.124089,"marketCap":1349277189},{"date":"2025-03-14","current":-9.547313,"twenty":-25.689992,"median":-21.491953,"eighty":-17.045645,"marketCap":1169794078},{"date":"2025-03-21","current":-10.235281,"twenty":-25.609403,"median":-21.417887,"eighty":-16.960589,"marketCap":1254088063},{"date":"2025-03-28","current":-9.33203,"twenty":-25.527539,"median":-21.321628,"eighty":-16.93886,"marketCap":1143416369},{"date":"2025-04-04","current":-7.64253,"twenty":-25.480594,"median":-21.202701,"eighty":-16.831205,"marketCap":936408691},{"date":"2025-04-11","current":-7.043483,"twenty":-25.340669,"median":-21.061141,"eighty":-16.666093,"marketCap":863009847},{"date":"2025-04-17","current":-8.672143,"twenty":-25.329214,"median":-21.042579,"eighty":-16.563339,"marketCap":1062562954},{"date":"2025-04-25","current":-11.068331,"twenty":-25.25285,"median":-20.951128,"eighty":-16.426861,"marketCap":1356158331},{"date":"2025-05-02","current":-12.790591,"twenty":-25.171712,"median":-20.933479,"eighty":-16.305436,"marketCap":1567180008},{"date":"2025-05-09","current":-12.551909,"twenty":-25.070517,"median":-20.891345,"eighty":-16.181125,"marketCap":1537935156},{"date":"2025-05-16","current":-9.774326,"twenty":-25.068859,"median":-20.829252,"eighty":-16.056814,"marketCap":1400885752},{"date":"2025-05-23","current":-9.895696,"twenty":-25.0453,"median":-20.693431,"eighty":-15.839386,"marketCap":1418280862},{"date":"2025-05-30","current":-9.000467,"twenty":-25.01052,"median":-20.672234,"eighty":-15.745511,"marketCap":1289973912},{"date":"2025-06-06","current":-8.619091,"twenty":-25.001825,"median":-20.550917,"eighty":-15.544032,"marketCap":1235314001},{"date":"2025-06-13","current":-8.920177,"twenty":-24.996225,"median":-20.487391,"eighty":-15.387426,"marketCap":1278466562},{"date":"2025-06-20","current":-8.679308,"twenty":-24.952868,"median":-20.449033,"eighty":-14.973238,"marketCap":1243944513},{"date":"2025-06-27","current":-8.462526,"twenty":-24.918331,"median":-20.434088,"eighty":-14.66039,"marketCap":1212874668},{"date":"2025-07-03","current":-8.175491,"twenty":-24.875783,"median":-20.408464,"eighty":-14.607558,"marketCap":1171735893},{"date":"2025-07-11","current":-7.587369,"twenty":-24.818526,"median":-20.385744,"eighty":-14.451133,"marketCap":1087444556},{"date":"2025-07-18","current":-7.840282,"twenty":-24.807686,"median":-20.281918,"eighty":-14.123781,"marketCap":1123692707},{"date":"2025-07-25","current":-7.334457,"twenty":-24.781668,"median":-20.180483,"eighty":-13.987039,"marketCap":1051196404},{"date":"2025-08-01","current":-7.145777,"twenty":-24.722332,"median":-20.085721,"eighty":-13.108576,"marketCap":1024154132},{"date":"2025-08-08","current":-5.211405,"twenty":-24.651853,"median":-19.971704,"eighty":-12.812535,"marketCap":932580977},{"date":"2025-08-15","current":-5.964179,"twenty":-24.61951,"median":-19.937893,"eighty":-12.626872,"marketCap":1067289809},{"date":"2025-08-22","current":-6.234546,"twenty":-24.540145,"median":-19.829477,"eighty":-12.490132,"marketCap":1115672078},{"date":"2025-08-29","current":-6.160517,"twenty":-24.4698,"median":-19.66456,"eighty":-12.119485,"marketCap":1102424552},{"date":"2025-09-05","current":-6.360074,"twenty":-24.389808,"median":-19.576169,"eighty":-11.77845,"marketCap":1138135274},{"date":"2025-09-12","current":-6.720564,"twenty":-24.139365,"median":-19.456275,"eighty":-11.057099,"marketCap":1202644966},{"date":"2025-09-19","current":-7.47695,"twenty":-24.11098,"median":-19.134734,"eighty":-10.896967,"marketCap":1338000122},{"date":"2025-09-26","current":-8.043434,"twenty":-24.072254,"median":-19.014985,"eighty":-10.567565,"marketCap":1439372495},{"date":"2025-10-03","current":-8.568076,"twenty":-24.020356,"median":-18.941828,"eighty":-10.325716,"marketCap":1533257136},{"date":"2025-10-10","current":-9.833009,"twenty":-23.986828,"median":-18.81071,"eighty":-10.186609,"marketCap":1759617036},{"date":"2025-10-17","current":-8.87063,"twenty":-23.947347,"median":-18.74276,"eighty":-9.917033,"marketCap":1587399198},{"date":"2025-10-24","current":-8.548764,"twenty":-23.914099,"median":-18.661907,"eighty":-9.852324,"marketCap":1529801259},{"date":"2025-10-31","current":-10.370526,"twenty":-23.886602,"median":-18.351918,"eighty":-9.836476,"marketCap":1855805594},{"date":"2025-11-07","current":-10.772858,"twenty":-23.868757,"median":-18.327399,"eighty":-9.850579,"marketCap":1927803018},{"date":"2025-11-11","current":-9.267723,"twenty":-23.860402,"median":-18.309202,"eighty":-9.825436,"marketCap":1952570132}],"updateTime":1762940739620},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GPCR\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1138016060","title":"Stock Track | Structure Therapeutics (GPCR) Soars 5% Pre-Market on Promising Obesity Drug Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1138016060","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138016060?lang=en_us&edition=fundamental","pubTime":"2025-11-10 23:00","pubTimestamp":1762786833,"startTime":"0","endTime":"0","summary":"Shares of Structure Therapeutics Inc. (NASDAQ: GPCR) are soaring 5.05% in pre-market trading on Monday, following the company's announcement of positive results from a mid-stage study of its...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GPCR"],"gpt_icon":0},{"id":"2582873987","title":"Press Release: Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2582873987","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582873987?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"SEP-631  Phase 1 Clinical Trial in Healthy Volunteers Ongoing. Robust Financial Position of $561.6 Million Expected to Support Operations at Least into 2029. SOUTH SAN FRANCISCO, Calif., Nov. 10, 2025  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today highlighted key business updates and upcoming milestones and reported financial results for the quarter ended September 30, 2025.\"In the third quarter, we made meaningful progress across our portfolio, highlighted by the selection of SEP-479 as our next-generation PTH1R agonist development candidate for hypoparathyroidism and the initiation of our Phase 1 clinical trial for SEP-631 which targets MRGPRX2 for mast cell-driven diseases,\" said Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna. \"Both programs exemplify the power of our Native Complex Platform to generate differentiated oral small-molecule GPCR therapies with the pote","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","03160","GPCR","BK4588","SEPN","BK4097","BK4555","BK4604","TM","BK4099","BK4599","BK4007","BK4585","LU2065732104.USD"],"gpt_icon":0},{"id":"2582145895","title":"The Bull Case For Structure Therapeutics (GPCR) Could Change Following Key Oral Obesity Drug Data Readouts","url":"https://stock-news.laohu8.com/highlight/detail?id=2582145895","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582145895?lang=en_us&edition=fundamental","pubTime":"2025-11-09 13:25","pubTimestamp":1762665917,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. recently reported a third quarter 2025 net loss of US$65.71 million, up from US$33.98 million a year earlier, and highlighted advancing milestones in its oral obesity drug pipeline including upcoming clinical data readouts and the expansion of its amylin receptor agonist program.\nThis combination of deepening financial losses and significant pipeline progress has been accompanied by ongoing analyst confidence in the company’s long-term research strategy.\nWe'll...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/the-bull-case-for-structure-therapeutics-gpcr-could-change-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/the-bull-case-for-structure-therapeutics-gpcr-could-change-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2581882283","title":"Stifel Nicolaus Reaffirms Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581882283","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581882283?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:47","pubTimestamp":1762530478,"startTime":"0","endTime":"0","summary":"Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $50.00...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/stifel-nicolaus-reaffirms-their-buy-rating-on-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SF","GPCR"],"gpt_icon":0},{"id":"2581015550","title":"Structure Therapeutics Inc  expected to post a loss of 39 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581015550","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581015550?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:14","pubTimestamp":1762514044,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc  expected to post a loss of39cents a share - Earnings Preview Structure Therapeutics Inc GPCR.OQ GPCR.O is expected to  show no change in quarterly revenue when it reports  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ16Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","BK4007"],"gpt_icon":0},{"id":"2581044019","title":"Structure Therapeutics Inc. unveils strategy to expand access to oral obesity treatments","url":"https://stock-news.laohu8.com/highlight/detail?id=2581044019","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581044019?lang=en_us&edition=fundamental","pubTime":"2025-11-07 07:35","pubTimestamp":1762472132,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc. detailed its approach to addressing the growing demand for obesity treatments, highlighting the scalability and accessibility of oral small molecule therapies compared to current injectable GLP-1 options. The company noted that despite over 100 million adults in the U.S. affected by overweight and obesity, current injectable treatments reach less than 5% of the addressable market. Structure Therapeutics projects significant market growth driven by broader access, improved affordability, new oral modalities, and expanding patient awareness. Internal and third-party estimates suggest that by 2030, 25-50% of the U.S. anti-obesity medication market could be served by oral therapies, appealing particularly to needle-hesitant adults and non-specialist prescribers. The company emphasized the convenience and potential cost benefits of oral treatments, as well as the increasing role of telehealth and primary care providers in obesity management. You can access the fu","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL1qN4KZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4599","BK4007"],"gpt_icon":0},{"id":"2581045377","title":"Structure Therapeutics Q3 loss widens to $65.7 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2581045377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581045377?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:41","pubTimestamp":1762465274,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Q3 loss widens to $65.7 mlnOverviewStructure Therapeutics reports Q3 net loss of $65.7 mln, compared to $34 mln in 2024Company maintains strong cash position of $799 mln, fundin","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2581012790","title":"BRIEF-Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581012790","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581012790?lang=en_us&edition=fundamental","pubTime":"2025-11-07 05:01","pubTimestamp":1762462911,"startTime":"0","endTime":"0","summary":"BRIEF-Structure Therapeutics Inc. Q3 Net Income USD -65.712 Million\n\n\nNov 06 (Reuters) - Structure Therapeutics Inc. Q3 operating expenses USD 73.787 million.\n\nQ3 income from operations USD -73.787 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nPLXCE3139:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599"],"gpt_icon":0},{"id":"2580213168","title":"Septerna to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2580213168","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580213168?lang=en_us&edition=fundamental","pubTime":"2025-11-03 21:00","pubTimestamp":1762174800,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Nov.  03, 2025  (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/03/3179226/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","GPCR","BK4599","SEPN"],"gpt_icon":0},{"id":"2580291074","title":"Citi adds ‘positive 90-day catalyst watch’ on Structure Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2580291074","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580291074?lang=en_us&edition=fundamental","pubTime":"2025-11-03 19:16","pubTimestamp":1762168571,"startTime":"0","endTime":"0","summary":"Citi opened a “positive 90-day catalyst watch” on shares of Structure Therapeutics (GPCR) while keeping a Buy rating on the name with a $60 price t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/citi-adds-positive-90-day-catalyst-watch-on-structure-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/citi-adds-positive-90-day-catalyst-watch-on-structure-therapeutics-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","BK4599","GPCR","LENZ","BK4007"],"gpt_icon":0},{"id":"2579222641","title":"Metsera the US obesity biotech at centre of Novo, Pfizer bidding war","url":"https://stock-news.laohu8.com/highlight/detail?id=2579222641","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579222641?lang=en_us&edition=fundamental","pubTime":"2025-10-31 00:36","pubTimestamp":1761842167,"startTime":"0","endTime":"0","summary":"Metsera the US obesity biotech at centre of Novo, Pfizer bidding warBy Bhanvi Satija LONDON, Oct 30 (Reuters) - Metsera MTSR.O has become the obesity drug market's hottest ticket.The New York-based bi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"0af834d50c548d8f93896c63d2f96f88","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nL4N3WB1WF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0868494617.USD","LU0345774391.USD","LU2360032135.SGD","LU1066051811.HKD","LU2417539215.USD","LU2087621335.USD","LU2242649171.HKD","IE0004445239.USD","VKTX","BK4534","SG9999014880.SGD","LU1221951046.USD","BK4532","LU0310800965.SGD","LU0738911758.USD","LU1880398471.USD","ALT","LU0648000940.SGD","LU2125154935.USD","LU1623119135.USD","LU2462157665.USD","LU0980610538.SGD","BK4581","MTSR","IE00BK4W5L77.USD","LU1712237335.SGD","LU1201861165.SGD","BK4573","LU1127390331.HKD","SGXZ31699556.SGD","BK4574","LU1201861249.SGD","LU0784384876.USD","LU2361045086.USD","LU0107464264.USD","LU0949170426.SGD","LU1023059063.AUD","LU0061474705.USD","LU1046421795.USD","LU0079474960.USD","PFE","IE00BK4W5M84.HKD","LU0823416689.USD","LU1244550494.USD","LU1974910355.USD","LU0648001328.SGD","LU1221951129.SGD","GPCR"],"gpt_icon":1},{"id":"1124178700","title":"SIHUAN PHARM (00460) Signs Collaboration Agreement with U.S.'s AbaloneBio to Jointly Develop Next-Generation Weight Loss and Muscle-Building Therapy, Further Expanding GPCR Target Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=1124178700","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124178700?lang=en_us&edition=fundamental","pubTime":"2025-10-30 08:14","pubTimestamp":1761783261,"startTime":"0","endTime":"0","summary":"SIHUAN PHARM (00460) announced that the group has formally entered into a collaboration agreement with U.S. biotech firm AbaloneBio (Abalone). Under the agreement, the two parties will collaborate...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4599","GPCR","00460","BK1515","BK4007","BK1593","BK1191","BK1600"],"gpt_icon":0},{"id":"2576852981","title":"Structure Therapeutics, Inc. Sponsored ADR (GPCR) Receives a Buy from Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2576852981","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576852981?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:57","pubTimestamp":1760965034,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-receives-a-buy-from-piper-sandler-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4599","GPCR"],"gpt_icon":0},{"id":"2574467022","title":"Structure Therapeutics (GPCR): Assessing Valuation After Recent Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2574467022","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574467022?lang=en_us&edition=fundamental","pubTime":"2025-10-12 06:22","pubTimestamp":1760221337,"startTime":"0","endTime":"0","summary":"Structure Therapeutics (GPCR) shares have caught the attention of investors recently as the company’s stock has returned over 58% in the past 3 months. This strong upward move has prompted questions about what is driving this momentum and whether it is sustainable.\nSee our latest analysis for Structure Therapeutics.\nLooking beyond the rapid 44% one-month share price return, Structure Therapeutics has more than doubled in the past quarter, indicating a surge in momentum and renewed optimism...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-assessing-valuation-after-recent","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-gpcr/structure-therapeutics/news/structure-therapeutics-gpcr-assessing-valuation-after-recent","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2571760357","title":"Press Release: Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2571760357","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2571760357?lang=en_us&edition=fundamental","pubTime":"2025-09-30 04:01","pubTimestamp":1759176060,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept. 29, 2025  -- Septerna, Inc. , a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor  drug discovery, today announced the appointment of Keith Gottesdiener, M.D., to its board of directors. A seasoned biotechnology executive with over 30 years of experience advancing medicines from discovery through commercialization, Dr. Gottesdiener will serve as chairperson of a newly constituted R&D Committee of the Board.\"Dr. Gottesdiener's exceptional track record of successfully advancing novel therapeutics from discovery through development to approval, combined with his deep expertise in regulatory strategy and clinical development across multiple therapeutic areas, will be invaluable as we advance our lead programs and build Septerna into a premier GPCR therapeutics company,\" said Jeffrey Finer, M.D., Ph.D., Chief Executive Officer and Co-founder of Septerna. \"His appointment comes at a pivotal time as we advance our lead p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GPCR","BK4604","SEPN","BK4555","03160","BK4007","BK4585","BK4599","TM","BK4099","BK4588"],"gpt_icon":0},{"id":"2568418518","title":"Cantor Fitzgerald Sticks to Its Buy Rating for Structure Therapeutics, Inc. Sponsored ADR (GPCR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2568418518","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568418518?lang=en_us&edition=fundamental","pubTime":"2025-09-17 23:56","pubTimestamp":1758124591,"startTime":"0","endTime":"0","summary":"In a report released today, Prakhar Agrawal from Cantor Fitzgerald reiterated a Buy rating on Structure Therapeutics, Inc. Sponsored ADR, with a pr...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/cantor-fitzgerald-sticks-to-its-buy-rating-for-structure-therapeutics-inc-sponsored-adr-gpcr-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR"],"gpt_icon":0},{"id":"2567121565","title":"Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from LifeSci Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2567121565","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567121565?lang=en_us&edition=fundamental","pubTime":"2025-09-16 08:46","pubTimestamp":1757983615,"startTime":"0","endTime":"0","summary":"LifeSci Capital analyst Patrick Dolezal maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR yesterday and set a price target of $...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/structure-therapeutics-inc-sponsored-adr-gpcr-gets-a-buy-from-lifesci-capital-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","BK4007","BK4599"],"gpt_icon":0},{"id":"2564802076","title":"Structure Therapeutics Inc. to Participate in Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564802076","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564802076?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:31","pubTimestamp":1756816311,"startTime":"0","endTime":"0","summary":"Structure Therapeutics Inc., a clinical-stage global biopharmaceutical company focused on developing novel oral small molecule therapeutics for metabolic diseases, including obesity, will participate in the Cantor Global Healthcare Conference on Wednesday, September 3, 2025. The event will feature a fireside chat and 1x1 meetings with the company's management.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Structure Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on September 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDLwd1vn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4007","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","LU0314104364.USD","GPCR","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BGHQF748.EUR","LU2210149790.SGD","BK4599","LU2210150020.SGD","BK4588"],"gpt_icon":0},{"id":"2562465757","title":"Septerna to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2562465757","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562465757?lang=en_us&edition=fundamental","pubTime":"2025-08-27 20:00","pubTimestamp":1756296000,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Aug.  27, 2025  (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug di","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/27/3139942/0/en/Septerna-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEPN","BK4599","BK4007","GPCR"],"gpt_icon":0},{"id":"2558983466","title":"Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2558983466","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558983466?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:01","pubTimestamp":1754942460,"startTime":"0","endTime":"0","summary":"Advancing Selection of Next-Generation Oral Small Molecule PTH1R Agonist for Clinical Development Initiating Phase 1 Trial for SEP-631, MRGPRX2 NAM Program, for Mast Cell Diseases Updated Cash Runway ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3131210/0/en/Septerna-Highlights-Business-Progress-and-Reports-Second-Quarter-2025-Financial-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2211815571.USD","PRGS","LU2065732104.USD","BK4599","LU1992135399.USD","COO","BK4588","LU2272731600.USD","SEPN","GPCR","LU1992135472.HKD","BK4198","BK4585","GB00BDT5M118.USD","BK4007","LU2272731782.SGD","BK4097"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":35,"code":"91000000","status":"200"}]}}